ClinicalTrials.gg

Program

Embibatinib

Also written as “HS-10382”, “MK-4208” and “TERN-701”.

In Hansoh Pharmaceutical Group's pipeline, BCR-ABL (STAMP). Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase, led by 2 companies.

Furthest: phase 3, since Oct 12, 20267 company-led studies, 5 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group44 open or runningphase 3since Oct 12, 2026May 6, 2022Feb 2027phase 1 · NCT07933224
Merck31 open or runningphase 2since Nov 8, 2023Nov 8, 2023Nov 30, 2029phase 2 · NCT06163430
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10382 (STAMP, Terns's TERN-701), phase 1, as of Aug 26, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2022First study: phase 1 study in Leukemia, Myeloid, Chronic-PhaseNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT05367700 · 108 planned · China
  2. Nov 8, 2023Merck's first study: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to MerckMerck · NCT06163430 · 330 planned · United States, Australia, France and more
  3. Jul 19, 2024Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHansoh Pharmaceutical Group · NCT06530810 · 100 planned
  4. Sep 18, 20262 phase 1 studies in HealthyMerck · NCT07839000, NCT07838987
  5. Oct 12, 2026Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositivePhase 3 reachedHansoh Pharmaceutical Group · NCT07885293 · 408 planned · China
  6. Nov 2, 2026Phase 1 study in Healthy VolunteersHansoh Pharmaceutical Group · NCT07933224 · 32 planned · China

Ahead

  1. Feb 2027Primary completion: phase 1 study in Healthy VolunteersHansoh Pharmaceutical Group · NCT07933224
  2. Jul 2029Primary completion: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHansoh Pharmaceutical Group · NCT07885293
  3. Nov 30, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMerck · NCT06163430

TargetBeta

“BCR-ABL (STAMP)”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
nilotinibruleNovartisphase 457
asciminibruleNovartisphase 416
olverembatinibruleAscentage Pharma Group Internationalphase 310
TQB3911Sino Biopharmaceuticalphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07933224Healthy Volunteers · China1Not yet recruitingHansoh Pharmaceutical GroupFeb 202732
NCT07885293Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China3Not yet recruitingHansoh Pharmaceutical GroupJul 2029408
NCT07839000Healthy · United States1CompletedMerckApr 3, 20268
NCT07838987Healthy · United States1CompletedMerckJun 30, 2026196
NCT06530810Leukemia, Myelogenous, Chronic, BCR-ABL Positive1Not yet recruitingHansoh Pharmaceutical GroupMay 8, 2026100
NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more2RecruitingMerckNov 30, 2029330
NCT05367700Leukemia, Myeloid, Chronic-Phase · China1RecruitingHansoh Pharmaceutical GroupDec 30, 2024108

How it is read

Names in the registry

  • “HS-10382”, 2 entries
  • “Embibatinib”, 1 entry
  • “MK-4208”, 1 entry
  • “TERN-701”, 1 entry
  • “HS-10382+Flumatinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.